Articles from 908 Devices Inc.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024.

Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences.

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming virtual Craig-Hallum Bioprocessing Conference.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming Canaccord Genuity 44th Annual Growth Conference.

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of 908 Devices’ acquisition of RedWave Technology, can now quantify nearly 5,000 airborne chemicals. XplorIR empowers fire departments, HAZMAT teams and other first responders with mission-critical information and enables decisions around personal protective equipment, ensures swift remediation efforts and reduces dangers to first responders and the public.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical identification of bulk materials. FTIR (Fourier Transform Infrared), an optical spectroscopy technology, is highly regarded for its specific substance identification abilities across a broad range of bulk materials.

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a variety of settings, from military applications to correctional facilities.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announce a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares’ Cell Shuttle system, a fully integrated, scalable, cell therapy manufacturing platform. The collaboration between the two companies aims to further advance the efficiency, safety, and cost-effectiveness of large-scale cell therapy manufacturing.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced that it has expanded access to its leading trace detection technology in its handheld MX908 device through the addition of a weatherproof, digital communications port, thereby enabling companies to integrate the device into their systems to enhance the safety of their users and the public.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System. The combination of the companies’ automation technologies will help advance the development of life-saving cell and gene therapies by providing insights into and control of one of the largest components of cell therapy development and manufacturing.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces today that it has been awarded a total of $10.4 million in purchase orders from the United States Air Force and Air National Guard Fire & Emergency Services Program for its MX908 handheld mass spectrometry device with Aero module.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces that it has entered the initial production phase of the Aerosol and Vapor Chemical Agent Detector (AVCAD) program. The company and its partner on the project, Smiths Detection, will initially produce 122 systems in this next phase.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK, an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended June 30, 2023.

908 Devices Inc, (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces that several Tennessee drug task forces, law enforcement agencies and county sheriffs’ offices have chosen to implement the company’s MX908 handheld mass spectrometer to enhance the speed and efficiency of their drug identification processes.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MX908 Beacon, a unique remote area monitoring system that can detect and identify aerosolized and vapor threats. Beacon’s area monitoring capabilities enable remote and continuous operation with more than eight hours of battery life and 16 hours of standby time.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the second quarter 2023 before market open on Tuesday, August 8, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming William Blair 43rd Annual Growth Stock Conference.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2023.

908 Devices Inc., (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced that National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, has adopted REBEL at-line media analyzers in their process development to inform and optimize cell culture feed strategies and media design. REBEL provides insights into cell metabolism to enable Resilience process engineers to measure spent media samples to monitor amino acid depletion during a monoclonal antibody perfusion process. Resilience demonstrated, using REBEL, a 50% increase in titer while reducing cost of goods by adding back only the nutrients the cells have depleted.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2023 before market open on Tuesday, May 9, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2022.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Cowen 43rd Annual Healthcare Conference in Boston, MA.

908 Devices Inc., (Nasdaq: MASS) a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2022 before market open on Tuesday, March 7, 2023. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced the launch of MAVEN, a device for on-line monitoring and control of glucose and lactate in cell culture and fermentation processes. MAVEN empowers biopharma companies to make timely decisions based on highly sensitive, real-time measurements. Taking measurements as frequently as every two minutes, MAVEN operates without having to manually draw samples out of the bioreactor due to its novel aseptic sampling approach. This improves process understanding, saves operator time and reduces the risk of process contamination--which in turn accelerates development workflows.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today shared details on the positive impact of the MX908 handheld mass spec device on correctional facility customers across the U.S. in detecting illegal drugs through incoming mail. The MX908 is used to detect and identify illicit drugs, protecting correctional officers, inmates and other bystanders in the process. The device’s sensitivity and specificity ensures trace amounts of drugs are detected and false alarms are greatly reduced.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2022.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, continues to equip its life science customers with actionable intelligence at the point-of-need, enabling them to drive advancements in biotherapeutic development.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the availability of a downloadable target pack for the MX908® to enable identification of toxic pesticides. Developed in conjunction with the United States Forest Service (USFS), an agency of the U.S. Department of Agriculture (USDA), this enhanced pesticide identification capability empowers responders with critical intelligence about toxic pesticides so they can take swift and appropriate action.

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that its collaboration with CPI is demonstrating the value of at-line cell culture media analysis to inform feeding strategies for improved cell growth in bioprocessing applications. Using data from 908 Devices’ REBEL™ desktop device, CPI process engineers optimized nutrients of a monoclonal antibody-expressing cell line to increase titer and control toxic metabolites.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2022.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications. 908 Devices expects the acquired technology to enable its mass spec devices as on-line bioprocess monitors.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming Canaccord Genuity 42nd Annual Growth Conference.

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 9, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis. The presentations, which include one oral and eleven posters, highlight technology to accelerate drug development workflows, and include collaborators such as Boehringer Ingelheim, Genentech, University of Washington, Fudan University, and Dana-Farber Cancer Institute.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming William Blair 42nd Annual Growth Stock Conference.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced updates to its MX908 handheld mass spec device, adding new capabilities to streamline workflows and improve field safety for first responders. The device will now include enhanced Bluetooth features with remote applications for iPhone mobile devices, as well as a broader range of drugs, including fentanyl analogs and synthetic opioids and cannabinoids.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is partnering with the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), an academic-industry research consortium dedicated to implementing bioengineering innovations that enhance the development and manufacture of complex biotherapeutics. As part of this mission, researchers are now utilizing 908 Devices’ REBEL™ analyzer to improve process monitoring and control methods in multiple AMBIC projects.

908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, is collaborating with UK-based, deep-tech innovation organization CPI on a project to optimize mammalian cell culture media and feeding strategies to improve growth, protein titer and protein quality attributes. CPI researchers are utilizing 908 Devices’ REBEL™ desktop device for at-line cell culture media analysis, helping to identify and then control key process parameters in bioprocessing workflows.

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in the following virtual investor conferences.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2021.

908 Devices (NASDAQMASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, and the United States Forest Service (USFS), an agency of the United States Department of Agriculture (USDA), are collaborating on a research effort to extend the capabilities of the MX908 handheld device for rapid detection of toxic pesticides used in illegal marijuana grows on federal lands.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in the following virtual investor conferences.

908 Devices Inc. (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of a public offering of shares of its common stock, with 3,150,000 shares being offered by the Company at a public offering price of $32.00 per share. In addition, 908 Devices has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares of common stock from the Company. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by 908 Devices, are expected to be approximately $100.8 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on November 15, 2021, subject to the satisfaction of customary closing conditions.

908 Devices Inc. (NASDAQMASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public offering of shares of its common stock, with 2,750,000 shares being offered by the Company pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 412,500 shares of common stock from the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September 30, 2021.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced at the American Society for Mass Spectrometry (ASMS) conference today a new Oligos assay kit for its ZipChip device that enables fast and accurate identification and quantitation of oligonucleotides. Using this new Oligos kit with the ZipChip device, biopharmaceutical lab personnel now have an easy method for high-resolution separation and mass spec sample introduction without the use of harsh ion-pairing reagents.

At the American Society of Mass Spectrometry (ASMS) conference October 31 to November 4 in Philadelphia, 908 Devices Inc. (Nasdaq: MASS) is presenting several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications. The company, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is also launching a new ZipChip assay kit that enables fast and accurate identification and quantitation of oligonucleotides.

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2021 before market open on Thursday, November 4, 2021. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended June 30, 2021.